CARDIFF ONCOLOGY, INC. Interest Paid, Including Capitalized Interest, Operating and Investing Activities
CARDIFF ONCOLOGY, INC. (CRDF) reported Interest Paid, Including Capitalized Interest, Operating and Investing Activities of $0 for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaid · last filed 2019-08-08
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2018 was $22.48K, a 96.64% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2017 was $668.47K, a 39.43% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2016 was $1.10M, a 3.93% increase from fiscal 2015.
- CARDIFF ONCOLOGY, INC. interest paid, including capitalized interest, operating and investing activities for fiscal 2015 was $1.06M, a 149.73% increase from fiscal 2014.
| Period end | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 3 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 6 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 9 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 12 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 170 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 173 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 176 month |
|---|---|---|---|---|---|---|---|
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2019-08-08 | $0.00 derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-05-07 | $0.00 derived: sum of 3 quarters · filed 2019-05-07 | $6.07K derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | $6.07K derived: sum of 3 quarters · filed 2019-08-08 | $22.48K 10-K · filed 2019-03-06 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $6.07K derived: sum of 2 quarters · filed 2019-08-08 | $22.48K 10-Q · filed 2018-11-07 | $40.62K derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-06-30 | $6.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $22.48K 10-Q · filed 2019-08-08 | $40.62K derived: sum of 3 quarters · filed 2019-08-08 | $60.99K derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-03-31 | $16.42K 10-Q · filed 2019-05-07 | $34.55K derived: sum of 2 quarters · filed 2019-05-07 | $54.93K derived: sum of 3 quarters · filed 2019-05-07 | $384.84K derived: sum of 4 quarters · filed 2019-05-07 | |||
| 2017-12-31 | $18.13K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $38.51K derived: sum of 2 quarters · filed 2019-03-06 | $368.43K derived: sum of 3 quarters · filed 2019-03-06 | $668.47K 10-K · filed 2019-03-06 | |||
| 2017-09-30 | $20.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $350.29K derived: sum of 2 quarters · filed 2018-11-07 | $650.33K 10-Q · filed 2018-11-07 | $947.78K derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $329.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $629.95K 10-Q · filed 2018-08-03 | $927.40K derived: sum of 3 quarters · filed 2018-08-03 | $1.20M derived: sum of 4 quarters · filed 2018-08-03 | |||
| 2017-03-31 | $300.04K 10-Q · filed 2018-05-08 | $597.49K derived: sum of 2 quarters · filed 2018-05-08 | $866.99K derived: sum of 3 quarters · filed 2018-05-08 | $1.13M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2016-12-31 | $297.45K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $566.95K derived: sum of 2 quarters · filed 2018-02-26 | $827.46K derived: sum of 3 quarters · filed 2018-02-26 | $1.10M 10-K · filed 2018-02-26 | |||
| 2016-09-30 | $269.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $530.01K derived: sum of 2 quarters · filed 2017-11-09 | $806.23K 10-Q · filed 2017-11-09 | $1.07M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | $260.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $536.73K 10-Q · filed 2017-08-09 | $803.35K derived: sum of 3 quarters · filed 2017-08-09 | $1.07M derived: sum of 4 quarters · filed 2017-08-09 | |||
| 2016-03-31 | $276.21K 10-Q · filed 2017-05-10 | $542.83K derived: sum of 2 quarters · filed 2017-05-10 | $807.96K derived: sum of 3 quarters · filed 2017-05-10 | $1.07M derived: sum of 4 quarters · filed 2017-05-10 | |||
| 2015-12-31 | $266.62K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $531.74K derived: sum of 2 quarters · filed 2017-03-15 | $796.87K derived: sum of 3 quarters · filed 2017-03-15 | $1.06M 10-K · filed 2017-03-15 | |||
| 2015-09-30 | $265.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $530.25K derived: sum of 2 quarters · filed 2016-11-09 | $795.38K 10-Q · filed 2016-11-09 | $972.13K derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-06-30 | $265.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $530.25K 10-Q · filed 2016-08-04 | $707.00K derived: sum of 3 quarters · filed 2017-03-15 | $883.75K derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-03-31 | $265.13K 10-Q · filed 2016-05-10 | $441.88K derived: sum of 2 quarters · filed 2017-03-15 | $618.63K derived: sum of 3 quarters · filed 2017-03-15 | $683.78K derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2014-12-31 | $176.75K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $353.50K derived: sum of 2 quarters · filed 2017-03-15 | $418.65K derived: sum of 3 quarters · filed 2017-03-15 | $425.26K 10-K · filed 2017-03-15 | |||
| 2014-09-30 | $176.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $241.91K derived: sum of 2 quarters · filed 2015-11-09 | $248.51K 10-Q · filed 2015-11-09 | $254.63K derived: sum of 4 quarters · filed 2016-03-10 | |||
| 2014-06-30 | $65.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $71.76K 10-Q · filed 2015-08-10 | $77.88K derived: sum of 3 quarters · filed 2016-03-10 | ||||
| 2014-03-31 | $6.60K 10-Q · filed 2015-05-05 | $12.72K derived: sum of 2 quarters · filed 2016-03-10 | $16.06K 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $6.12K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $9.46K 10-K · filed 2016-03-10 | $9.46K 10-K · filed 2014-03-17 | ||||
| 2013-09-30 | $3.34K 10-Q · filed 2014-11-06 | $3.34K 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |